Summary
Global Markets Direct’s, ‘Ensemble Therapeutics Corporation - Product Pipeline Review - 2016’, provides an overview of the Ensemble Therapeutics Corporation’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Ensemble Therapeutics Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Ensemble Therapeutics Corporation
- The report provides overview of Ensemble Therapeutics Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Ensemble Therapeutics Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Ensemble Therapeutics Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Ensemble Therapeutics Corporation’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ensemble Therapeutics Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ensemble Therapeutics Corporation’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Ensemble Therapeutics Corporation Snapshot 5
Ensemble Therapeutics Corporation Overview 5
Key Information 5
Key Facts 5
Ensemble Therapeutics Corporation - Research and Development Overview 6
Key Therapeutic Areas 6
Ensemble Therapeutics Corporation - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Ensemble Therapeutics Corporation - Pipeline Products Glance 14
Ensemble Therapeutics Corporation - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Ensemble Therapeutics Corporation - Drug Profiles 16
Small Molecules to Inhibit Cyclophilin A for Hepatitis B 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Small Molecules to Inhibit Cyclophilin D for Cardiovascular and Central Nervous System 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Small Molecules to Inhibit IAP for Oncology 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Small Molecules to Inhibit USP9X for Metastatic Cancer 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Small Molecules to Inhibit PCSK9 for Cardiovascular Disease 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecules to Inhibit USP28 for Oncology 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecules to Inhibit USP30 for Oncology and Parkinson's disease 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Ensemble Therapeutics Corporation - Pipeline Analysis 23
Ensemble Therapeutics Corporation - Pipeline Products by Target 23
Ensemble Therapeutics Corporation - Pipeline Products by Route of Administration 24
Ensemble Therapeutics Corporation - Pipeline Products by Molecule Type 25
Ensemble Therapeutics Corporation - Pipeline Products by Mechanism of Action 26
Ensemble Therapeutics Corporation - Dormant Projects 27
Ensemble Therapeutics Corporation - Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 29
Disclaimer 30
List of Tables
Ensemble Therapeutics Corporation, Key Information 5
Ensemble Therapeutics Corporation, Key Facts 5
Ensemble Therapeutics Corporation - Pipeline by Indication, 2016 7
Ensemble Therapeutics Corporation - Pipeline by Stage of Development, 2016 8
Ensemble Therapeutics Corporation - Monotherapy Products in Pipeline, 2016 9
Ensemble Therapeutics Corporation - Partnered Products in Pipeline, 2016 10
Ensemble Therapeutics Corporation - Partnered Products/ Combination Treatment Modalities, 2016 11
Ensemble Therapeutics Corporation - Out-Licensed Products in Pipeline, 2016 12
Ensemble Therapeutics Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Ensemble Therapeutics Corporation - Preclinical, 2016 14
Ensemble Therapeutics Corporation - Discovery, 2016 15
Ensemble Therapeutics Corporation - Pipeline by Target, 2016 23
Ensemble Therapeutics Corporation - Pipeline by Route of Administration, 2016 24
Ensemble Therapeutics Corporation - Pipeline by Molecule Type, 2016 25
Ensemble Therapeutics Corporation - Pipeline Products by Mechanism of Action, 2016 26
Ensemble Therapeutics Corporation - Dormant Developmental Projects,2016 27
List of Figures
Ensemble Therapeutics Corporation - Pipeline by Top 10 Indication, 2016 7
Ensemble Therapeutics Corporation - Pipeline by Stage of Development, 2016 8
Ensemble Therapeutics Corporation - Monotherapy Products in Pipeline, 2016 9
Ensemble Therapeutics Corporation - Partnered Products in Pipeline, 2016 10
Ensemble Therapeutics Corporation - Out-Licensed Products in Pipeline, 2016 12
Ensemble Therapeutics Corporation - Pipeline by Target, 2016 23
Ensemble Therapeutics Corporation - Pipeline by Molecule Type, 2016 25
Ensemble Therapeutics Corporation - Pipeline Products by Mechanism of Action, 2016 26
